Revenues - (Tables)

9 Months Ended

Sep. 30, 2020

Revenue from Contract with Customer [Abstract]

The following table presents a summary of total revenues (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Xyrem	$	447,809	$	425,644	$	1,302,492	$	1,207,173
Defitelio/defibrotide	50,241		37,604		140,387		125,159
Erwinaze/Erwinase	20,145		34,024		90,560		122,545
Vyxeos	30,825		29,581		90,113		89,886
Zepzelca	36,941		—		36,941		—
Sunosi	9,116		987		19,618		987


Other	1,872		4,481		5,246		13,325
Product sales, net	596,949		532,321		1,685,357		1,559,075
Royalties and contract revenues	3,939		5,381		12,693		20,946
Total revenues	$	600,888	$	537,702	$	1,698,050	$	1,580,021

The following table presents a summary of total revenues attributed to geographic sources (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
United States	$	548,410	$	492,366	$	1,542,990	$	1,436,160
Europe	45,778		35,037		125,229		106,956
All other	6,700		10,299		29,831		36,905
Total revenues	$	600,888	$	537,702	$	1,698,050	$	1,580,021

Summary of Revenues from Customers Representing More Than 10% of Total Revenues

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
ESSDS	74	%	79	%	77	%	76	%
McKesson	10	%	12	%	11	%	14	%

Summary of a Reconciliation in Contract Liabilities from Contracts with Customer

The following table presents a reconciliation of our beginning and ending balances in contract liabilities from contracts with customers for the nine months ended September 30, 2020 (in thousands):


	Contract Liabilities
Balance as of December 31, 2019	$	9,581

Amount recognized within royalties and contract revenues	(3,540)
Balance as of September 30, 2020	$	6,041